Cibc World Markets Corp Has $5.43 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Cibc World Markets Corp raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 15.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,629 shares of the medical research company's stock after purchasing an additional 3,604 shares during the period. Cibc World Markets Corp's holdings in IQVIA were worth $5,429,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Private Trust Co. NA lifted its position in IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock valued at $115,000 after purchasing an additional 47 shares during the period. Pine Valley Investments Ltd Liability Co lifted its position in IQVIA by 0.5% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock valued at $2,247,000 after purchasing an additional 50 shares during the period. Howard Capital Management Inc. increased its stake in shares of IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after acquiring an additional 54 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock valued at $1,068,000 after acquiring an additional 56 shares during the last quarter. Finally, Cypress Wealth Services LLC increased its stake in shares of IQVIA by 4.8% in the 4th quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock valued at $244,000 after acquiring an additional 57 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Upgrades and Downgrades

A number of analysts have recently commented on IQV shares. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a research note on Wednesday, December 11th. BTIG Research cut IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Stifel Nicolaus lowered their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Barclays lowered their price target on IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research note on Monday, February 3rd. Finally, JPMorgan Chase & Co. lowered their price target on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research note on Tuesday, February 18th. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $249.05.

IQVIA Stock Up 0.9 %

Shares of IQV traded up $1.59 during mid-day trading on Friday, hitting $185.85. 3,242,588 shares of the company's stock were exchanged, compared to its average volume of 1,239,812. The company has a market cap of $32.77 billion, a PE ratio of 24.78, a P/E/G ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 52 week low of $179.28 and a 52 week high of $254.54. The company has a 50-day simple moving average of $194.94 and a 200 day simple moving average of $208.45. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.